

### **CytoTools AG announces a strategic reinforcement of the management board**

- CytoTools AG extends its management board to three persons
- Former Novartis manager, Dr. Markus Weissbach, takes over the newly created division Registration and Clinical Development

Darmstadt, 17<sup>th</sup> October 2013 – The CytoTools AG, a technology holding company with participations in the field of pharmaceuticals and medical products, announces the extension of the managerial board to three persons. The company has been successful in securing the services of the physician Dr. Markus Weissbach, a very experienced manager from the big pharma / clinical research field, for the key division: Registration and Clinical Development. In his career, Dr. Weissbach held a series of management positions with clinical contract research companies and in research and clinical development at large pharmaceutical companies. Among other posts, he was Chief Medical Officer at Novartis Vaccines & Diagnostics, Chairman of the Board at Aptiv Solutions, President of ICON Europe and a director at Takeda Pharmaceuticals and Knoll AG. He moved from the supervisory board to the management board of CytoTools AG. Thus the CytoTools AG emphasises the important target of successfully and quickly completing the ongoing clinical trials.

At the current time, in which the European Phase III study for DermaPro® has begun successfully, and to which, after the Baltic States and Germany, five further countries will join, CytoTools is being strengthened in this position with a very experienced manager. Dr. Dirk Kaiser, a board member of the CytoTools AG, is delighted and summarized: „With Dr. Weissbach, CytoTools has been successful in winning over a top manager from the pharmaceutical industry for our dynamic biotechnology company. This shows that we are on the verge of developing from a research company to a product-oriented enterprise. We look forward with eager anticipation to the results of the current studies and the impending trials in further indications. We see much greater potential in the active substance DermaPro® which will already be demonstrated by the expected market launch in India next year. This strengthening of our personnel will allow us to implement new projects even faster and more effectively.”

Now, as well as the dermatological projects, further candidates in the development pipeline of CytoTools AG will be directed on the route towards clinical trials.

The new board and a five-strong clinical team creates the personnel prerequisites for the transformation of new and self-developed substances into clinical development. With this, the perception of the CytoTools AG, which was long seen as a single product company, will fundamentally change and the whole potential of the technology and knowledge base can be realised.

## PRESS RELEASE



*This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

**CytoTools AG**, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: around 58% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

### **Contact:**

CytoTools AG  
Dr. Mark Andre Freyberg  
Klappacher Str. 126  
D-64285 Darmstadt  
Tel.: +49-6151-95158-12  
Fax: +49-6151-95158-13  
E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

### **Press contact:**

cometis AG  
Ulrich Wiehle  
Unter den Eichen 7  
D-65195 Wiesbaden  
Tel.: +49-611-205855-11  
Fax: +49-611-205855-66  
E-Mail: [wiehle@cometis.de](mailto:wiehle@cometis.de)